Articles tagged with Chemotherapy
A new biomaterial-based cancer vaccine has shown promise in treating aggressive triple-negative breast cancer (TNBC) in mice, with 100% survival rate after a subsequent injection of cancer cells. The vaccine combines chemotherapy and immunotherapy to generate a sustained anti-cancer response.
A recent study found that healthcare utilization declined by 23% in March and 52% in April, with diagnostic procedures like mammograms and colonoscopies dropping by over 65%. The switch to telemedicine created disparities among lower-income and non-white patients, who had lower rates of telehealth use.
Researchers found that administering immunotherapy in combination with chemotherapy earlier in the course of disease can slow cancer progression. Combining the therapies also kills myeloid-derived suppressor cells, which appear to overpower immunotherapies, thereby improving response rates.
A research team at POSTECH developed a machine learning technique that uses transcriptome information from artificial organoids to predict anti-cancer drug response. This method increases predictive accuracy by selecting only relevant biomarkers, which was previously limited by false signals in conventional machine learning.
HSE Faculty of Chemistry scientists discovered a new anti-cancer molecule, diphenylisoxazole, which is easily synthesized using available compounds. The molecule inhibits tubulin polymerization and shows effectiveness on both sea urchin embryos and human cancer cells.
An agent-based computer model shows that delayed implementation of social distancing measures and low adherence can increase COVID-19 cases in urban areas. Maintaining personal behaviors like face mask use after easing social distancing measures also has a significant impact.
A new study reveals racial and socioeconomic disparities in treating patients with extensive-stage small cell lung cancer. Black patients are less likely to receive chemotherapy compared to white patients, despite improved survival rates. Insurance status and education level also impact treatment and survival outcomes.
Scientists created more sensitive optogenetic tools to investigate cell signaling pathways in cancer and neuropathic pain. The new tools revealed how chemotherapy drugs disrupt signaling, enabling the development of targeted therapeutic compounds.
A Purdue University scientist is working on a technique that uses LED light to determine if certain chemotherapy options will work for specific patients. The method, which was published in Scientific Reports, shows promise for improving personalized medicine and reducing side effects.
A new study suggests that gut bacteria are partially responsible for metabolic changes leading to weight gain in women after chemotherapy treatment. The research found that the pre-treatment microbiome of patients who gained weight was different from those who did not, and fecal transplantation resulted in glucose intolerance in germ-f...
Researchers have developed a new cancer-specific anticancer drug that can prevent drug resistance and reduce side effects. The drug is designed to release an anticancer agent along with a drug-resistance inhibitor in cancer cells, effectively treating cancers without recurrence or treatment failure.
Researchers developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR. The treatment showed significantly smaller tumors in tumor-bearing mice with no apparent side effects.
A newly developed prodrug has been shown to selectively target and destroy glioblastoma cells, improving outcomes when combined with standard therapies. In a mouse model study, the drug extended survival by more than a factor of three and was curative in nature.
Scientists have developed a technique that quickly identifies optimal synergistic combinations of anticancer drugs, reducing tumour growth by 80% and outperforming chemotherapy. The technology, called TGMO, achieves results in under two weeks, paving the way for personalized, effective, and safe cancer treatment.
A research team from Chinese Academy of Sciences proposes an innovative immune cocktail therapy combining ICT with other approaches to enhance cancer treatment. The therapy achieves anti-tumor effects by enhancing T cell priming, killing tumor cells, and generating immune memory T cells.
Researchers have identified the cellular process by which Cisplatin chemotherapy causes neuronal damage, revealing that it induces senescence of peripheral neurons through overexpression of the p21 protein. This discovery provides new targets for neuroprotective treatments to alleviate or avoid the adverse effects of Cisplatin.
Researchers develop a nano-carrier for medications that can control release in diseased cells only. Synthetic DNA structures stabilize the particles and can be triggered by microRNA molecules found in cancer cells.
This observational study examines survival rates and chemotherapy use before surgery in US women with advanced ovarian cancer between 2004-2016. The study found improvements in treatment and survival rates over time, with more patients receiving chemotherapy before surgery.
Researchers at NTU Singapore have devised a novel approach to kill cancer cells using a nanoparticle coated with an amino acid that selectively targets and destroys cancer cells. The 'Trojan horse' nanoparticle, called Nano-pPAAM, was tested in lab experiments and found to be effective in killing cancer cells with high specificity.
A genome-wide association study has identified genetic markers associated with a higher risk of developing capecitabine-induced hand-foot syndrome. The study found that patients with low levels of R-cadherin and involucrin were more likely to experience severe skin symptoms.
A phase III clinical trial led by Queen Mary University of London shows that immunotherapy drug avelumab significantly improves survival in patients with the most common type of bladder cancer. Avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
A study found that using proton pump inhibitors (PPIs) worsened survival rates and disease progression in patients with urothelial cancer treated with atezolizumab. PPI use did not affect overall survival or response to chemotherapy.
Researchers found a pattern of gut bacteria, specifically SCFAs, that may influence the effectiveness of chemotherapy in breast cancer patients. These chemicals play a role in the immune system and may help patients mount an immune response against cancer cells.
Scientists have developed a new method to combat cancer by using molecular fibers that target the acidic and reactive environment of cancer cells. The approach has shown promising results in laboratory tests, with cancer cells dying within four hours.
Researchers at City of Hope found that Andrographis paniculata, a natural botanical, is effective in killing chemo-resistant colon cancer cells when used in conjunction with chemotherapy. The study's goal was to develop a non-toxic treatment that could succeed in killing cancer cells.
Researchers developed a combination treatment using gas embolization and chemotherapy, achieving tumor regression and reducing regrowth in hepatocellular carcinoma models. The method is less invasive and more precise than traditional treatments.
Researchers have used single-cell RNA sequencing to profile transcriptome-level changes in response to DNA damage across individual cancer cells. The study found three distinct groups of genes activated in response to chemotherapy, revealing new insights into why some cancer cells survive while others die.
Recent studies suggest that adding sofosbuvir and daclatasvir to standard care may reduce the duration of hospital stays for COVID-19 patients. The combination showed a lower median duration of stay and reduced mortality rates compared to standard care alone.
Researchers developed a comprehensive study on nanoprodrugs (NPDs) inside cancer cells, revealing their internalization rate, intracellular localization, and degradation. The study shows that NPDs consistently absorbed by cells as intact particles before being transported into lysosomes.
Scientists have unraveled the structure and mechanism of DNA polymerase ζ, an enzyme that replicates through daily DNA-damaging events. This discovery offers valuable insights into developing effective inhibitors to make cancer cells more sensitive to chemotherapy.
A new study aims to investigate how chemotherapy affects children's brain development and cognitive function, particularly sensory processing, memory, and attention. The researchers hope to develop protective interventions to prevent permanent harm from 'chemo brain'.
The combination of first-line nivolumab and ipilimumab demonstrated an improvement in overall survival compared to platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma. The study showed a two-year overall survival rate of 40.8% for the treatment arm vs 27.0% for the chemotherapy arm.
The addition of sintilimab to pemetrexed and platinum chemotherapy significantly improved progression-free survival in patients with non-squamous non-small cell lung cancer, with a nearly two-fold increase observed. The overall response rate was also higher in the sintilimab-combination group compared to the placebo combination.
A new study uses patient-specific tumor organoids to identify the most effective chemotherapy protocol for treating advanced stages of colon and appendiceal cancer. The approach shows promise in tailoring treatment to individual patients, potentially increasing life expectancy.
Researchers found that chemotherapy is rarely used to treat adults with localized sarcoma, affecting only 22% of patients. Facilities performing more surgeries for sarcoma tend to use chemotherapy more frequently.
Researchers at Stanford University have created a handheld, portable device to measure ammonia levels in blood. The device, which assesses ammonia levels from a finger or earlobe prick, can report results in less than a minute and is significantly more efficient than current methods.
Researchers at the University of Arkansas have developed a new nano drug candidate that kills triple negative breast cancer cells. The discovery aims to target breast cancer cells directly, reducing adverse and toxic side effects associated with chemotherapy.
The study of Jurassic fossils from northeastern China provides evidence that ancient catkin-yew species existed during the Middle-Late Jurassic period. The fossils, which bear a striking resemblance to modern catkin-yews, demonstrate morphological stasis and are among the most completely known fossil Taxaceae.
Indian University researchers identify circulating tumor DNA and cells in plasma as indicators of disease recurrence and survival. The study, published in JAMA Oncology, enables stratification of patients for targeted therapies.
Small interfering RNA (siRNA) shows potential for treating human diseases by selectively silencing pathological pathways. The review examines siRNA therapeutics in preclinical and clinical trials, challenges faced in siRNA therapy, and the feasibility of combining siRNA with anticancer drugs.
A new clinical trial has tested a cocktail of chemotherapy drugs for patients with metastatic pancreatic cancer, showing a median survival time of 14.5 months and a 1-year survival rate of 60.9%. The treatment strategy involves injections of paclitaxel into the abdomen and gemcitabine and nab-paclitaxel into the blood.
A study of over 2,800 breast cancer patients found that those who were overweight or obese had poorer outcomes when treated with docetaxel. The researchers believe this is due to the fat in their bodies absorbing part of the drug before it can reach the tumor.
Researchers at Hokkaido University found that inflammatory changes in tumors caused by chemotherapy trigger drug resistance in blood vessels, resulting in poorer cancer outcomes. The team also discovered a treatment strategy involving the combination of an ABCB1 inhibitor and anticancer drugs to overcome this resistance.
Researchers have identified a promising new strategy to target tumors with metabolic weaknesses, particularly in patients with IDH mutant gliomas. Combining chemotherapy and PAR glycohydrolase inhibitors has shown promise in enhancing treatment effectiveness.
A Yale Cancer Center study confirms the effectiveness of combining chemotherapy and trastuzumab in treating aggressive uterine serous carcinoma, a rare form of endometrial cancer. The treatment significantly improves progression-free survival, with no increase in toxicity.
UConn researchers use patented nanoparticle with common chemotherapy drug doxorubicin to target leukemia stem cells, reducing treatment-resistant relapses. The nanoparticle enables slow release of the drug to bone marrow, improving survival rates and inhibiting cancerous stem cells.
In a phase 2 trial, berzosertib, an ATR protein inhibitor, was found to significantly extend progression-free survival for patients with ovarian cancer compared to chemotherapy alone. The drug targets a protein crucial for cancer cell growth and division.
A novel treatment for advanced mesothelioma has been shown to be safe and effective, with a 70.3% disease control rate and median overall survival rate of 8.5 months. The transarterial chemoperfusion treatment may improve the quality of life for patients who have few treatment options.
The COVID-19 pandemic is worsening existing drug shortages in the US, particularly for cancer treatments and critical care medications. Experts recommend improved communication and sharing mechanisms among hospitals and healthcare providers to address these shortages.
A new study reveals that chemotherapy and cancer contribute to the development of neuropathy, a condition affecting millions of cancer patients. Researchers found that cancer itself causes significant distress to neurons, while chemotherapy amplifies this effect, leading to more severe trauma.
Researchers found that ovarian cancer patients with a modified BRCA1 gene do not respond better to platinum chemotherapy or have a better prognosis than those with the normal functioning gene. However, they did live longer on these treatments compared to those without any gene modifications.
Oncology pharmacy practitioners worldwide are struggling with limited and restricted PPE supply, making it difficult for them to provide high-quality cancer care. In a study, half of the surveyed countries reported impaired access to essential medications, including anti-infective agents and anticancer medications.
Dietary changes can trigger changes in the host's response to chemotherapy drugs, increasing or decreasing their effectiveness and toxicity. Researchers found that common components of daily diets can have a profound impact on cancer treatment outcomes.
A new study suggests that genetic testing for acute myeloid leukemia (AML) can be delayed without negatively impacting patient outcomes. For stable patients, waiting a week or more for test results allows doctors to assign the correct subgroup and select targeted treatment.
A Phase 2 clinical trial has shown a novel treatment protocol to be effective in patients with intravascular large B-cell lymphoma (IVLBCL), achieving two-year survival rates of up to 76% and overall survival rates of 92%. The treatment, combining conventional drugs with high-dose methotrexate and intrathecal chemotherapy, has been fou...
A phase III clinical trial found that the addition of cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes, but showed similar activity in patients. The study suggests potential for non-platinum based alternatives in certain biomarker subgroups.
A large international trial found that pembrolizumab more than doubled the progression-free survival time of patients with a specific subtype of advanced bowel cancer, compared to chemotherapy. The treatment also showed durable benefits, with 48.3% of patients experiencing no disease progression after two years.
A WPI-led research team has identified drugs that target triple-negative breast cancer tumors in mice without inducing toxic side effects. The targeted therapies use molecular recognition units to specifically target the tumors, reducing their sizes and eliminating them.
An exploratory study found that metformin combined with rapamycin was well-tolerated in patients with stable or responding metastatic pancreatic ductal adenocarcinoma (mPDA) after 6 months of chemotherapy. The combination was associated with exceptionally long survival rates and improved disease stability.
Boosting the activity of tumor proteasomes could improve chemotherapy treatment outcomes and enhance immunotherapy for aggressive triple-negative breast cancer. Researchers analyzed 3,500 breast tumors to make this finding.